Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

This study is testing a combination of cancer drugs — tretinoin (a vitamin A derivative), arsenic trioxide, and possibly a third drug called gemtuzumab ozogamicin — in people newly diagnosed with a type of leukemia called acute promyelocytic leukemia (APL), a fast-moving blood cancer. **You may be eligible if...** - You have been newly diagnosed with acute promyelocytic leukemia (APL), confirmed by genetic testing - You are able to understand and sign an informed consent form - You may have already started emergency treatment with some of these drugs before enrolling **You may NOT be eligible if...** - Your APL diagnosis has not been confirmed by the required genetic tests - You are unable to provide informed consent - You have had prior treatment for APL beyond what is allowed (some early emergency treatment is permitted) Talk to your doctor to see if this trial is right for you.